These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21029824)

  • 1. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
    Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
    Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
    Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
    Zhang HC; Guo JH; Fang Q; Zheng YA; Sun YM; Zhu WQ; Wan Z; Guo JX; Ge JB; Han SM
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):798-801. PubMed ID: 15949393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.